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Abstract
With little in the way of effective therapeutic strategies to target the
innate immune response, a better understanding of the critical
pathways regulating neutrophil and macrophage responses in
inflammation is key to the development of novel therapies. Hypoxia
inducible factor (HIF) was originally identified as a central trans-
criptional regulator of cellular responses to oxygen deprivation.
However, the HIF signalling pathway now appears, in myeloid cells
at least, to be a master regulator of both immune cell function and
survival. As such, understanding the biology of HIF and its
regulators may provide new approaches to myeloid-specific
therapies that are urgently needed.
Introduction
Despite the evolution of respiratory and cardiovascular
systems in multicellular higher organisms, the presence of
physiological oxygen gradients within and across tissues is
well described. At sites of tissue injury and inflammation,
oxygen gradients become exaggerated – and it is within
relatively oxygen-deplete tissue environments that myeloid
cells are required to migrate and function. These sites are
typified by empyemas, healing wounds and inflamed joints,
where oxygen tensions in the range of 0 to 3 kPa are well
documented [1]. It therefore makes sense that myeloid cells
have adapted to function at these sites of relative tissue
hypoxia, although subversion of this response may also be
important in the persistent inflammation associated with inflam-
matory arthritides, notably rheumatoid arthritis where tissue
hypoxia is also linked to disease severity and progression.
Hypoxia inducible factor (HIF), a transcriptional regulator of
cellular responses to oxygen deprivation, plays a crucial role
in the regulating myeloid cell function in hypoxia and in
inflammation more broadly. The roles of HIF in regulating key
myeloid cell functions and signalling pathways are discussed
in the present review and are summarized in Figure 1.
Adaptation of myeloid cells to hypoxia
The major pathway for sustainable production of ATP utilizes
oxygen in the mitochondrial electron transport system, the
process known as oxidative phosphorylation. Within the
majority of cells there is a critical intracellular oxygen partial
pressure required for respiration (the Pasteur point), below
which cells produce ATP through the nonoxygen-requiring
process of glycolysis, resulting in the accumulation of lactic
acid. The relative importance of these aerobic and anaerobic
pathways is highly dependent on the cell systems examined.
Myeloid cells are unique in that they have adapted to operate
by anaerobic metabolism, even when transiting oxygen-
replete areas, with neutrophils incorporating 85% of their
glucose uptake into lactate even under resting aerobic
conditions [2]. As such, mitochondrial inhibitors have been
shown to have no effect on inflammatory responses, in
contrast to glycolytic inhibitors that significantly reduce the
intracellular ATP concentrations and functional capacity of
these cells [2]. With this in mind, the enhanced phagocytic
capacity of neutrophils cultured in hypoxia [3] and the
profound effects of hypoxia on tissue macrophage
phagocytosis [4], chemokine receptor expression [5] and β2-
integrin-mediated adhesion in vitro [6] are less surprising.
Neutrophils are programmed to undergo apoptosis consti-
tutively following their release from the bone marrow into the
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circulation. Neutrophil apoptosis is critical for the resolution
of inflammation, with direct effects of apoptosis on neutrophil
function and indirect effects on macrophage release of
proinflammatory and anti-inflammatory cytokines [7]. Indirect
evidence that neutrophil apoptosis occurs in vivo has now
been supported by work highlighting the potential of driving
neutrophil apoptosis as a therapeutic strategy in a range of
murine models, including arthritis [8]. Neutrophil apoptosis is
modulated by chemokines (IL-8, granulocyte–macrophage
colony-stimulating factor, TNFα) and mediators induced by
pathogens (bacterial lipopolysaccharide) [9,10], providing a
mechanism by which the tissue environment can modulate
the longevity of neutrophils. In addition to modulation of
neutrophil apoptosis by secreted factors, we and other
workers have described the profound regulation of neutrophil
apoptosis by physiological hypoxia [11,12]. This is in direct
contrast to the effects of hypoxia on most other primary cell
types where an induction of cell death is described [13], and
is reversible, with neutrophils recovered to a normoxic
environment being able to regain their full apoptotic potential.
Moreover, direct hypoxic neutrophil survival requires active
protein synthesis and is independent of the phospha-
tidylinositol 3-kinase pathway so fundamental to the
functional competence of these cells. This pathway can,
however, be enhanced in a phosphatidylinositol 3-kinase-
dependent manner; an effect at least partially dependent on
the hypoxic release of the novel neutrophil survival factor
macrophage inflammatory protein 1β [11,12]. In macro-
phages, whilst acute hypoxia has been shown to induce
apoptosis, repeated exposure of RAW264.7 macrophages to
hypoxia can result in the selection of an apoptosis-resistant
population [14]. Myeloid cells would therefore appear to have
adapted to facilitate their persistence at sites of inflammation,
where other cell types have a reduced lifespan. This
prolongation of functional longevity may, however, prove to
be of detriment to the host organism in the context of
autoimmune disease. Hypoxia has itself been shown to be
critical in regulating the pro-apoptotic and anti-apoptotic
effects of rheumatoid synovial fluid upon neutrophils [15], and
is therefore a potentially important regulator of neutrophil
function and lifespan within the inflamed joint in vivo.
The mechanisms by which hypoxia and, more specifically, the
HIF pathway have been shown to modulate myeloid cell
function remain to be fully elucidated and represent an area
of active research interest. The better characterized pathways
are detailed below (and summarized in Figure 1) but remain
largely incomplete and only partially understood. Whilst much
work has focused recently on the importance of the HIF
pathway, it is likely that this will not reflect the sole
mechanism for the functional regulation of these cells. For
example, there is evidence of hypoxic regulation of HIF-
independent transcription factors ATF4 and Egr-1 [16] and of
the bHLH transcription factor inhibitor Id2 described in vitro
in hypoxia-exposed monocyte-derived macrophages [17].
Oxygen sensing and the hypoxia inducible
factor hydroxylase pathway
Over the past 20 years it has become apparent that all cells
have an intrinsic ability to sense and adapt to tissue oxygen
levels through the oxygen-sensitive transcription factor, HIF.
HIF is a heterodimeric beta helix–loop–helix protein com-
posed of an unstable oxygen-sensitive alpha subunit and a
constitutively expressed stable beta subunit (aryl hydrocarbon
nuclear translocator) [18,19]. Three HIFα subunits have been
identified to date in higher organisms (HIF-1α, HIF-2α and
HIF-3α) [20-22], with most detailed information available for
HIF-1α and HIF-2α. Differential cellular expression of HIFα
genes, with genetic conservation in eukaryotes and multiple
splice variants of HIF-3α, support an essential and
nonoverlapping role for the HIFs, although the precise nature
of their functional diversity remains to be fully characterized.
All HIFα subunits are subject to regulation in two ways: first,
proteasomal degradation following hydroxylation of two highly
conserved prolyl residues (Pro-402 and Pro-564) by members
of the prolyl hydroxylase domain-containing family (PHD)
[23,24]; and secondly, transcriptional inactivation following
asparaginyl hydroxylation by factor inhibiting HIF [25-27].
Prolyl hydroxylation enables proteosomal degradation of the
HIFα subunit through high-affinity binding to the von
Hippel–Lindau (VHL) E3 ubiquitin ligase [18,24,28]. Four
PHD proteins that can hydroxylate HIF have currently been
identified (PHD1, PHD2 and PHD3, and a recently described
fourth enzyme P4H-TM), with all four displaying wide tissue
expression but in a differential cellular localization – nuclear
(PHD1), cytoplasmic (PHD2), nuclear and cytoplasmic
(PHD3), and endoplasmic reticulum (P4H-TM) [29,30].
PHDs and factor inhibiting HIF all display an absolute
requirement for dioxygen, Fe(II) and 2-oxoglutarate, with PHD1
and PHD3 also regulated by ubiquitination as targets for the
E3 ubiquitin ligases Siah1a and Siah2 [31]. At sites of reduced
oxygen tension, therefore, reduced PHD and factor inhibiting
HIF hydroxylase activity permits stabilization and transcriptional
activation of HIF, resulting in the modulation of multiple HIF
effector genes, which contain hypoxia response elements [22],
to facilitate the cellular adaptive responses to hypoxia. These
responses include the function of enhancing local oxygen
delivery by promoting erythropoiesis and angiogenesis and by
the metabolic adaptation to oxygen deprivation through the
upregulation of glycolytic enzymes and glucose transporters. In
excess of 60 HIF target genes have been identified to date,
with gene expression profiling confirming significant overlap
between HIF-1 and HIF-2 regulated genes. With a degree of
nonredundancy of function, and differential basal and cell-
specific expression of the HIFα isoforms described, however, it
is likely that the regulation of gene expression by the HIF
pathway is complex, and that characterizing the regulation of
the relative changes in expression between the isoforms may
be important in understanding the subversion of physiological
hypoxic responses in disease states.With an oxygen concentration that enables a half-maximal
catalytic rate for oxygen well above tissue oxygen con-
centrations, the hydroxylase enzymes are well placed to
function over all physiologically relevant oxygen tensions
[32,33], enabling the HIF system to operate as a highly
efficient oxygen sensor in vivo. The HIF-dependent hypoxic
induction of PHD2 and PHD3 mRNA and protein [34] allows
further adaptation to oxygen thresholds within individual cells,
since this is dependent on previous oxygen exposure, and
may therefore explain the ability of the HIF pathway to
respond to the wide variety of tissue oxygen tensions in vivo
in a cell-specific way. In addition to the oxygen-dependent
regulation of hydroxylase activity, the metabolic intermediates
fumarate and succinate have also been shown to modulate
hydroxylase activity and HIF signalling, as have the
intracellular availability of iron and ascorbate and the local
concentration of reactive oxygen species. A role for
sumoylation and histone acetylase inhibition [35] has also
been postulated but remains controversial, with reports of
both increased and decreased HIF stability following HIF
sumoylation [36,37]. Whilst oxygen sensing remains the
fundamental regulator of HIF signalling, it is clear from the
above that modulation of HIF activity by intermediates may
play a physiological role at sites of inflammation that are
characterized by low levels of glucose and high levels of
reductive metabolites.
Hypoxia inducible factor and myeloid cell
function
In addition to the key role of HIF in regulating the cellular
responses to hypoxia, work from Randall Johnson’s group has
shown that HIF also plays a fundamental role in regulating
inflammation. Using myeloid-targeted HIF-1α knockout mice,
they described a critical role for HIF-1α in regulating neutro-
phil and mononuclear cell glycolysis [38]. In HIF-1α-deficient
myeloid cells, this resulted in a reduction in ATP pools,
accompanied by profound impairment of cell aggregation,
motility, invasiveness, and bacterial killing. In vivo this
correlated with the ablation of sodium dodecyl sulphate-
induced cutaneous inflammation and a reduction in synovial
infiltration, pannus formation and cartilage destruction in an
immune complex-mediated inflammatory arthritis model.
Further studies by this group subsequently demonstrated the
importance of HIF in the regulation of phagocytic bactericidal
capacity in vivo [39], with decreased bactericidal activity and
exaggerated systemic spread of infection in conditional
HIF-1α knockouts compared with littermate controls. Impor-
tantly, using human pathogens (Group A Streptococcus,
methicillin-resistant  Staphylococcus aureus,  Pseudomonas
aeruginosa, and Salmonella species), they also showed
induction of HIF-1α expression and transcriptional activity in
macrophages that was independent of oxygen tension.
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Figure 1
Central role of hypoxia inducible factor in the regulation of myeloid cell-mediated inflammation. Under conditions of reduced oxygenation,
hydroxylase inhibition and the presence of bacteria/bacterial lipopolysaccharide (LPS), hypoxia inducible factor (HIF) is stabilized and modulates
the expression of hypoxia response element (HRE)-responsive genes – resulting in the upregulation of myeloid cell glycolysis, microbicidal
proteases, phagocytosis and vascular permeability, and consequently enhanced macrophage and neutrophil recruitment, bacterial killing and
persistent myeloid cell-mediated inflammation. PHD, prolyl hydroxylase domain-containing enzyme; FIH, factor inhibiting HIF; IKKB, IκB kinase beta;
SLC11a1, phagocyte-specific solute particle carrier 11A1 protein.Interestingly there was a divergence in myeloid cell functional
regulation, with HIF-1α regulating production of nitric oxide,
the granule proteases cathepsin G and neutrophil elastase,
and the antimicrobial peptide cathelicidin, but not endothelial
transmigration or respiratory burst activity. Bacterial lipopoly-
saccharide was also shown to directly increase HIF-1α
transcription and to decrease PHD2-mediated and PHD3-
mediated HIF-1α degradation in macrophages in a Toll-like
receptor 4-dependent fashion. HIF-1α deletion in these
macrophages was subsequently shown to be protective
against bacterial lipopolysaccharide-induced mortality and to
be associated with the downregulation of cytokines in these
cells – including TNFα, IL-1, IL-4, IL-6 and IL-12, which are
implicated in the pathogenesis of sepsis syndrome [40].
The importance of the differential regulation of these func-
tional responses by HIF-1α remains to be explored. Further-
more, the relative contributions of HIF-2 and the different
isoforms of HIF-3 to these functional pathways have yet to be
clarified. Work looking at differential expression of the HIF
isoforms in vitro and in vivo in monocytes, monocyte-derived
macrophages and tumour-associated macrophages is also
complex, with Burke and colleagues describing the prefer-
ential induction of HIF-1 in human macrophages in vitro
following hypoxic stimulation, and in vivo in different tumour
sites [17]. In contrast, work by Talks and colleagues des-
cribes HIF-2 as the predominant isoform in differentiated
promonocytic cells [41]. More recently, Elbarghati and
colleagues have shown the regulation of both HIF-1 and
HIF-2 by hypoxia in human monocyte-derived macrophages
[16], and postulated the enhanced stability of HIF-2 over
HIF-1 in the context of more prolonged hypoxic exposure.
Interestingly, in macrophages isolated from rheumatoid joints,
HIF-1 has been described previously as being the pre-
dominant isoform [42].
To enable neutrophils to migrate from the oxygen-replete
circulation to the site of tissue damage, the neutrophils under-
go a process of selectin-mediated rolling and β2-integrin-
mediated adhesion [43]. This process of diapedesis is itself
modified by HIF-1α expression, with HIF-1 being a
transcriptional regulator of CD18, the β2-integrin beta subunit
[44]. Once neutrophils have migrated down an oxygen gradient
to the site of tissue damage, it is the regulation of their function
longevity that is thought to be critical for the resolution of
inflammatory responses. Given the profound survival effect of
hypoxia on neutrophils aged in vitro [11,12], and the critical
role for HIF in regulating cellular responses to hypoxia, we
studied the importance of HIF itself in regulating neutrophil
apoptosis. We showed a marked reduction in survival of bone-
marrow-derived HIF-1α-deficient neutrophils compared with
controls, following their culture under hypoxic conditions [45].
Together these data highlight the importance of HIF-1α in
coordinating appropriate and effective innate immune
responses, but also identify a potential role for dysregulation of
HIF in conditions of inappropriate or persistent inflammation.
Direct evidence that the HIF pathway regulates innate immune
responses  in vivo in humans is provided by a series of
experiments in which we isolated peripheral blood neutrophils
from individuals with germline mutations in the vhl gene. Since
these individuals retain one intact copy of the vhl allele, this
enabled us to study the effects of heterozygous VHL
expression in human neutrophils [3]. We described a partial
hypoxic phenotype, which manifests as a reduction of
constitutive rates of neutrophil apoptosis, as enhanced
neutrophil susceptibility to hydroxylase inhibition and as
enhanced neutrophil phagocytosis of heat-killed bacteria
under normoxic conditions [3]. Further studies of individuals,
for example, with homozygous mutations in the vhl alleles with
Chuvash polycythaemia may further clarify the importance of
the HIF pathway in the pathogenesis of human disease in vivo.
NF-κ κB, HIF-1α α and innate immunity
The first evidence of a direct interaction between NF-κB and
HIF signalling pathways was provided by a search for non-
HIF substrates of the HIF hydroxylase enzymes by Cockman
and colleagues [46]. They describe the efficient hydroxylation
of asparginyl residues within the ankyrin repeat domain of the
IκB proteins p105 (NFKB1) and IκBα, but no functional
consequence of this interaction with respect to NF-κB-
dependent transcription. A possible role in the stoichiometric
competition between HIF and other ankyrin repeat domain-
containing proteins was subsequently raised. Concurrently,
Cummins and colleagues proposed a model of hypoxic de-
repression of NF-κB activity through a reduction in PHD1-
dependent hydroxylation of the IκB kinase beta (IKKβ)
classical pathway regulator, although again the cellular
consequences of this association were not defined and only
modest NF-κB activation was described [47]. HIF-1α has
also been shown, however, to promote the expression of
NF-κB-regulated inflammatory cytokines [40], and loss of
HIF-1α results in the downregulation of hypoxia-induced
NF-κB message in murine bone-marrow-derived neutrophils
[45]. Whilst these data clearly highlight crosstalk between
the HIF and NF-κB pathways, the consequences of these
associations both in vitro and  in vivo and the variation
between the cell types studied makes functional
interpretation of these existing data difficult.
Given the complex nature of the relationship between HIF-1α
and NF-κB and the central role of both the HIF and NF-κB
signalling pathways in the regulation of innate immune
responses, Rius and colleagues investigated the conse-
quence of IKKβ deficiency for the induction of HIF-1α target
genes and HIF-1α accumulation in macrophages using mice
deficient in IKKβ [48]. They show that loss of IKKβ results in
the defective induction of HIF target genes, with IKKβ
essential for HIF-1α accumulation following macrophage
exposure to bacteria. NF-κB activation without hypoxic
inhibition of the prolyl hydroxylase enzymes, however, was
insufficient for HIF-1α protein accumulation. Of note, IKKβ
was not required for the hypoxic induction of HIF-2α protein
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results propose IKKβ to be an important link between hypoxic
signalling, innate immunity and inflammation with NF-κB, a
critical transcriptional activator of HIF-1α. With no described
effect on HIF-2α signalling, the biological importance of this
association may, however, in part depend on the dominant
HIF subunit specific to the cell type and on the physiological
or disease conditions in which that cell is functioning.
Novel hypoxia inducible factor targets in the
innate immune response
Anaemia of chronic disease following the sequestration of
iron in the reticuloendothelial system has been recognized as
a clinically important entity for many decades [49]. Whilst the
increased iron retention by inflammatory macrophages has
also been well characterized [50], direct links between critical
signalling pathways involved in innate immune responses and
iron homeostasis have only recently been revealed.
Work by Peyssonnaux and colleagues initially described the
key iron regulator hepcidin to be regulated by the HIF/VHL
pathway [51]. Hepcidin is a small, acute-phase peptide
synthesized by the liver that limits iron export from macro-
phages through the inhibition of the major iron exporter
ferroportin [52]. Hepcidin is itself downregulated in condi-
tions of chronic anaemia and hypoxia. Using mice with
HIF-1α inactivated in hepatocytes alone, the authors showed
an HIF-1α dependence for hepcidin downregulation following
a diet-induced iron deficiency [51]. They were subsequently
able to show (indirectly) that HIF-1α binds to and negatively
trans-activates the hepcidin promoter. Importantly, however,
HIF-1α deletion alone was not sufficient to fully compensate
for iron-deficient loss of hepcidin, inferring that other factors
may also be involved – a potential role for HIF-2 in this
response again remains to be addressed.
Subsequent to that work, Tacchini and colleagues looked at
the effect of inflammatory and anti-inflammatory signals on
HIF-1-mediated transferrin receptor (TfR1) expression in
macrophages [53]. TfR1 represents one of three major
pathways required for the macrophage acquisition of iron
[54]. Its role in inflammatory iron sequestration is somewhat
controversial given the reported post-transcriptional
downregulation of TfR1 following prolonged in vitro exposure
of macrophages (10 to 24 hours) to bacterial lipopoly-
saccharide IFNγ [55]. Work by this group and others,
however, describes an initial early induction of TfR1 (30 min)
that involves the successive activation of NF-κB and HIF-1
signalling pathways [53]. Furthermore this induction of TfR1
was functionally important since it was associated with a
greater uptake of transferrin-bound iron by the RAW264.7
macrophages. This would thus represent an early transient
macrophage response to inflammatory stimuli that would
precede the role of hepcidin in maintaining the iron
sequestration by macrophages, again demonstrating a dual
regulation by NF-κB and HIF inflammatory pathways.
Whilst hypoxia and the HIF/hydroxylase pathway in the
regulation of myeloid cell function and survival is of direct
functional importance in regulation of innate immune
responses, a role for HIF in the regulation of heritable macro-
phage resistance to intracellular pathogens would clearly be
important for an individual’s overall disease risk. A genetic
basis for the protection of organisms from infection by intra-
cellular pathogens remains a relatively new concept, and was
first supported by work in mice through the cloning of a locus
that encodes a phagocyte-specific solute particle carrier
11A1 protein (SLC11a1) and protects in-bred mice from
infection by intracellular pathogens [56]. Despite this obser-
vation, no identifiable mutations in human SLC11a1 have
been reported despite obvious functional differences in
individual resistance to infection and inflammatory disease.
Bayele and colleagues proposed that quantitative differences
in SLC11A1 transcription may underlie human disease sus-
ceptibility [57]. They subsequently described the regulation
of allele expression by a Z-DNA-forming microsatellite within
the SLC11A1 promoter following its binding to HIF-1α. The
functional importance of this association was shown by an
attenuation  of macrophage responsiveness to Salmonella
typhimurium  following the targeted deletion of HIF-1α in
murine macrophages. As such the authors propose that HIF-1
may influence the heritable variation in innate resistance to
infection and inflammation through the regulation of gene
expression phenotypes. This would indeed make HIF the true
master regulator of innate immune myeloid cell-mediated
responses.
Conclusions
With a predominantly glycolytic metabolism, myeloid cells are
well placed to function within the oxygen-deplete environ-
ments in which they find themselves at sites of tissue injury
and infection. The importance of HIF in mediating their
transcriptional responses to relative physiological oxygen
tensions is now well described, with the oxygen-sensitive
hydroxylase enzymes critical in this response. Increasing
evidence for the oxygen-independent regulation of myeloid
cell function by the HIF pathway, and in particular HIF-1α,
now lends credence to a fundamental role of the HIF pathway
in regulating innate immune responses. This evidence would
appear to range from an inherited predisposition to inflam-
mation and microbial resistance to the regulation of bacterial
killing, migration and apoptosis. This has important
therapeutic implications both with respect to the enhanced
ability of organisms to effectively remove injurious stimuli and
with respect to the persistence of exaggerated myeloid cell-
mediated inflammatory responses associated acutely with
respiratory distress syndromes and more chronically with
diseases such as rheumatoid arthritis and chronic obstructive
pulmonary disease.
Clearly whilst the enhanced activity of HIF may thus be
important in the acute infectious disease setting, facilitating
microbial recognition and clearance by myeloid cells,
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development of inflammatory diseases, particularly – as in
arthritis, where hypoxia and inflammation co-exist. Any novel
therapeutic strategies will thus have to be very selective for
the disease pathways they are to target and, as a result, are
more likely to involve critical regulators of the HIF pathway
unique to that disease condition and considerably down-
stream of the global regulator itself. This makes the further
understanding of the HIF hydroxylase pathway and its
interactions with other key regulators of the innate immune
response – for instance, the NF-κB pathway – critical for the
development of novel therapeutic strategies.
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